Citation: A. Meager et al., Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega, J IMMUNOL M, 257(1-2), 2001, pp. 17-33
Authors:
Page, C
Dawson, P
Woollacott, D
Thorpe, R
Mire-Sluis, A
Citation: C. Page et al., Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations, J PHARM PHA, 52(1), 2000, pp. 19-26
Citation: A. Mire-sluis et al., The development of a World Health Organisation international standard for islet cell antibodies: the aims and design of an international collaborative study, DIABET M R, 15(1), 1999, pp. 72-77
Citation: A. Mire-sluis et R. Thorpe, Quality considerations for recombinant DNA-derived biological therapeutic products - A control perspective on cytokines, BIODRUGS, 11(6), 1999, pp. 367-376
Authors:
Giorgini, AE
Beales, PE
Mire-Sluis, A
Scott, D
Liddi, R
Pozzilli, P
Citation: Ae. Giorgini et al., Troglitazone exhibits immunomodulatory activity on the cytokine productionof activated human lymphocytes, HORMONE MET, 31(1), 1999, pp. 1-4
Authors:
Harrison, CN
Gale, RE
Pezella, F
Mire-Sluis, A
Machin, SJ
Linch, DC
Citation: Cn. Harrison et al., Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value, BR J HAEM, 107(1), 1999, pp. 139-147
Authors:
Tarelli, E
Mire-Sluis, A
Tivnann, HA
Bolgiano, B
Crane, DT
Gee, C
Lemercinier, X
Athayde, ML
Sutcliffe, N
Corran, PH
Rafferty, B
Citation: E. Tarelli et al., Recombinant human albumin as a stabilizer for biological materials and forthe preparation of international reference reagents, BIOLOGICALS, 26(4), 1998, pp. 331-346